In Silico Modeling and Production of New Vaccine Consisting of E7 Antigen Conjugated with Tetanus Toxin

Abstract

BACKGROUND AND OBJECTIVE: The cervical cancer is one of the main causes of death in women. Human Papilloma Virus (HPV) has been isolated in more than 98% of cervical cancer cases. The E7 has low capacity for induction immune response. Carrier proteins such as tetanus toxin are new approaches for increasing immune response against low immunogenic antigens. The aim of this study is production of new recombinant protein consisting of E7 antigen and tetanus toxin. METHODS: This study is experimental study and recombinant fusion protein consisting of E7 and tetanus toxin produced in bacterial expression system. The coding sequence of fusion protein obtained from NCBI. Molecular weight and epitopes verified using Polyacrylamide gel and western blot analysis. For prediction of immunogenicity, epitope database and analysis resource (IEDB) was used. FINDINGS: The presence of 42 kDa band in electrophoresis and epitopes in western blot analysis confirmed production of recombinant fusion protein. In silico modeling show that recombinant protein is stable (The parameter instability index (II) was near to 31.14) and has acceptable function in induction immune response (score of eliciting an immune response was close to 0.73). CONCLUSION: This study was focused on modeling, optimization and production recombinant fusion protein consisting of E7 protein and tetanus toxin.

Keywords

• Cervical cancer
• Human papilloma virus E7
• Recombinant protein
• Tetanus toxin